Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]